[HTML][HTML] A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major …
Q Zhao, B Fu, N Lyu, X Xu, G Huang, Y Tan… - Journal of Affective …, 2023 - Elsevier
Background Desvenlafaxine and duloxetine are selective serotonin and norepinephrine
reuptake inhibitors. Their efficacy has not been directly compared using statistical …
reuptake inhibitors. Their efficacy has not been directly compared using statistical …
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled …
KA Tourian, SK Padmanabhan, J Groark, C Brisard… - Clinical …, 2009 - Elsevier
Background: Major depressive disorder (MDD) is a common, chronic illness associated with
substantial disability and economic burden. Although a number of effective antidepressants …
substantial disability and economic burden. Although a number of effective antidepressants …
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
MR Liebowitz, AL Manley… - … medical research and …, 2008 - Taylor & Francis
Objective: To assess the efficacy, safety, and tolerability of 50-and 100-mg/day doses of
desvenlafaxine (administered as desvenlafaxine succinate), a serotonin-norepinephrine …
desvenlafaxine (administered as desvenlafaxine succinate), a serotonin-norepinephrine …
Efficacy of desvenlafaxine compared with placebo in major depressive disorder patients by age group and severity of depression at baseline
D Mosca, M Zhang, R Prieto… - Journal of Clinical …, 2017 - journals.lww.com
Purpose This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50
and 100 mg versus placebo across age groups and severity of depression at baseline in …
and 100 mg versus placebo across age groups and severity of depression at baseline in …
[HTML][HTML] A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with …
MR Liebowitz, KA Tourian, E Hwang, L Mele… - BMC psychiatry, 2013 - Springer
Background In an effort to establish the lowest effective dose of desvenlafaxine
(administered as desvenlafaxine succinate), we assessed the efficacy, safety, and …
(administered as desvenlafaxine succinate), we assessed the efficacy, safety, and …
Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician
S Reddy, C Kane, B Pitrosky, J Musgnung… - … medical research and …, 2010 - Taylor & Francis
Background: Major depressive disorder (MDD) is a common, seriously impairing illness.
Desvenlafaxine (administered as desvenlafaxine succinate) is the third serotonin …
Desvenlafaxine (administered as desvenlafaxine succinate) is the third serotonin …
[HTML][HTML] Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d for the treatment of major depressive disorder: a systematic review of clinical trials
MR Liebowitz, KA Tourian - The Primary Care Companion for CNS …, 2010 - psychiatrist.com
Objective: Desvenlafaxine is the third serotonin-norepinephrine reuptake inhibitor (SNRI)
approved by the US Food and Drug Administration for major depressive disorder (MDD) …
approved by the US Food and Drug Administration for major depressive disorder (MDD) …
Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials
PMJ Vis, M Baardewijk… - Annals of …, 2005 - journals.sagepub.com
BACKGROUND Duloxetine has joined venlafaxine on the antidepressant market as a
second serotonin–norepinephrine reuptake inhibitor. No previous studies have directly …
second serotonin–norepinephrine reuptake inhibitor. No previous studies have directly …
High-dose desvenlafaxine in outpatients with major depressive disorder
JM Ferguson, KA Tourian, GR Rosas - CNS spectrums, 2012 - cambridge.org
ObjectiveThis study investigated the safety and efficacy of long-term treatment with high-
dose desvenlafaxine (administered as desvenlafaxine succinate) in major depressive …
dose desvenlafaxine (administered as desvenlafaxine succinate) in major depressive …
Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients
N Iwata, KA Tourian, E Hwang, L Mele… - Journal of Psychiatric …, 2013 - journals.lww.com
Background. This study evaluated the efficacy and safety of low-dose desvenlafaxine
(administered as desvenlafaxine succinate) in treating major depressive disorder (MDD) …
(administered as desvenlafaxine succinate) in treating major depressive disorder (MDD) …